Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 27 06 2018
revised: 20 08 2018
accepted: 19 10 2018
pubmed: 26 10 2018
medline: 14 4 2020
entrez: 25 10 2018
Statut: ppublish

Résumé

To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors. We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness. With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.

Identifiants

pubmed: 30352907
pii: 1078-0432.CCR-18-2039
doi: 10.1158/1078-0432.CCR-18-2039
pmc: PMC6359971
mid: NIHMS1510880
doi:

Substances chimiques

Biomarkers, Tumor 0
Tumor Suppressor Protein p53 0
FGFR3 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

967-976

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221745
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA182587
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2018 American Association for Cancer Research.

Références

Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
JAMA Oncol. 2018 Jun 1;4(6):806-813
pubmed: 29596542
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Clin Cancer Res. 2005 Sep 15;11(18):6512-9
pubmed: 16166427
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Eur Urol. 2017 Oct;72(4):641-649
pubmed: 28601352
J Clin Oncol. 2013 Sep 1;31(25):3133-40
pubmed: 23897969
Eur Urol. 2015 Dec;68(6):970-7
pubmed: 26278805
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Eur Urol. 2008 Dec;54(6):1226-36
pubmed: 18715695
Eur Urol. 2015 Jun;67(6):1122-1133
pubmed: 25488681
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
J Urol. 2013 Apr;189(4):1214-21
pubmed: 23023150
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
J Natl Cancer Inst. 2012 Sep 19;104(18):1363-72
pubmed: 22933731
Nat Rev Cancer. 2018 Sep;18(9):527-528
pubmed: 30030494
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
BJU Int. 2012 Dec;110(11 Pt B):E583-9
pubmed: 22703159
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12129-34
pubmed: 17620607
BJU Int. 2009 Nov;104(10):1436-40
pubmed: 19689473
J Urol. 2000 Nov;164(5):1523-5
pubmed: 11025695
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Oncogene. 2008 Apr 24;27(19):2716-27
pubmed: 18037967
Ann Appl Stat. 2015 Sep;9(3):1533-1548
pubmed: 26594266
Lancet. 1993 Oct 30;342(8879):1087-8
pubmed: 8105314
Oncogene. 2001 Aug 9;20(35):4910-5
pubmed: 11521204
Springerplus. 2013 Aug 28;2:412
pubmed: 24024098
Genet Mol Res. 2014 Feb 20;13(1):1109-20
pubmed: 24634132
PLoS One. 2012;7(6):e38863
pubmed: 22685613
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
Am J Epidemiol. 2001 Mar 1;153(5):411-8
pubmed: 11226969
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Eur Urol. 2011 Oct;60(4):703-10
pubmed: 21684068

Auteurs

François Audenet (F)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. francois.audenet@gmail.com colemanj@mskcc.org solitd@mskcc.org.

Sumit Isharwal (S)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Eugene K Cha (EK)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Mark T A Donoghue (MTA)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Esther N Drill (EN)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Irina Ostrovnaya (I)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Eugene J Pietzak (EJ)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

John P Sfakianos (JP)

Department of Urology, Mount Sinai Hospital, New York, New York.

Aditya Bagrodia (A)

Department of Urology, UT Southwestern Medical Center, Dallas, Texas.

Paari Murugan (P)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.

Guido Dalbagni (G)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Timothy F Donahue (TF)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Jonathan E Rosenberg (JE)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Dean F Bajorin (DF)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Maria E Arcila (ME)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Jaclyn F Hechtman (JF)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Michael F Berger (MF)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Barry S Taylor (BS)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Hikmat Al-Ahmadie (H)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Gopa Iyer (G)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weil Cornell Medical College, New York, New York.

Bernard H Bochner (BH)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Weil Cornell Medical College, New York, New York.

Jonathan A Coleman (JA)

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. francois.audenet@gmail.com colemanj@mskcc.org solitd@mskcc.org.

David B Solit (DB)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. francois.audenet@gmail.com colemanj@mskcc.org solitd@mskcc.org.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weil Cornell Medical College, New York, New York.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH